GlassScriptPhysician profile
Pavan S Reddy
NPI 1932161155
$64,792.70
in general payments reported to CMS, 2019-2025
70 companies · $24K in 2025
The $24K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,876 · 2020: $11K · 2021: $2,752 · 2022: $3,413 · 2023: $1,302 · 2024: $19K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $4,712 · Travel and Lodging: $1,410 · Grant: $350 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,727.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,528.00 |
| Food and Beverage | $4,711.51 |
| Travel and Lodging | $1,410.17 |
| Grant | $350.00 |
| Education | $134.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $12,324.41 | 2019-2025 | Zepzelca |
| Emd Serono, INC. | $12,239.43 | 2019-2025 | Bavencio |
| Astrazeneca Pharmaceuticals LP | $10,025.19 | 2019-2025 | Truqap, Imfinzi, Enhertu |
| Daiichi Sankyo INC. | $6,795.70 | 2020-2025 | Enhertu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,568.68 | 2025 | |
| Celgene Corporation | $2,598.04 | 2019-2025 | Pomalyst, Reblozyl, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $2,222.56 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Taiho Oncology, INC. | $1,432.12 | 2019-2024 | |
| Geron Corporation | $1,200.00 | 2025 | Rytelo |
| Pfizer INC. | $1,169.97 | 2019-2025 | |
| Verastem, INC. | $1,143.90 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $1,056.62 | 2019-2025 | |
| Dova Pharmaceuticals | $1,004.09 | 2020-2021 | |
| Rigel Pharmaceuticals, INC. | $932.28 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Karyopharm Therapeutics INC. | $799.37 | 2020-2022 |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $513.84 | 2019-2025 | Lunsumio, Tecentriq, Phesgo |
| Verity Pharmaceuticals INC. | $500.00 | 2021 | |
| Astellas Pharma US INC | $421.68 | 2019-2025 | Padcev, Xtandi |
| Amgen INC. | $408.40 | 2019-2022 | |
| Janssen Biotech, INC. | $406.96 | 2019-2025 | Erleada, Rybrevant, Balversa |
| Abbvie INC. | $391.84 | 2019-2025 | |
| Seagen INC. | $372.88 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $346.53 | 2019-2025 | Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $270.20 | 2019-2025 | Fruzaqla, Iclusig, Ninlaro |
| Eisai INC. | $209.89 | 2019-2025 | |
| Puma Biotechnology, INC. | $161.83 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $153.52 | 2019-2023 | Imbruvica, Epkinly |
| Array Biopharma INC | $148.72 | 2019-2022 | |
| Kite Pharma, INC. | $147.93 | 2020-2023 | |
| Glaxosmithkline, LLC. | $143.74 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Epizyme, INC. | $141.18 | 2020-2022 | |
| Lilly USA, LLC | $127.26 | 2019-2025 | Verzenio |
| Genzyme Corporation | $124.70 | 2019-2024 | |
| Intuitive Surgical, INC. | $118.03 | 2025 | |
| Incyte Corporation | $83.67 | 2019-2025 | Monjuvi |
| US Oncology Corporate, INC. | $69.93 | 2021 | |
| Servier Pharmaceuticals LLC | $66.13 | 2022-2025 | |
| Acrotech Biopharma INC. | $64.33 | 2021-2024 | Beleodaq |
| Springworks Therapeutics, INC. | $61.99 | 2024-2025 | Ogsiveo |
| Lexicon Pharmaceuticals, INC. | $58.65 | 2023-2024 | Inpefa |
| Beigene USA, INC. | $49.86 | 2020-2021 | |
| Genmab U.S., INC. | $47.39 | 2023-2025 | Epkinly |
| Alexion Pharmaceuticals, INC. | $47.38 | 2022-2024 | Ultomiris |
| Sobi, INC | $45.95 | 2022-2025 | |
| Tersera Therapeutics LLC | $45.46 | 2020-2023 | Zoladex |
| Deciphera Pharmaceuticals INC. | $39.93 | 2023-2025 | Qinlock |
| Pharmacosmos Therapeutics INC. | $37.23 | 2023-2024 | Monoferric |
| Exelixis INC. | $34.24 | 2019-2020 | |
| Immunocore Limited | $31.59 | 2024-2025 | Kimmtrak |
| Clovis Oncology, INC. | $27.33 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.63 | 2020-2021 | |
| Aurobindo Pharma USA, INC. | $24.95 | 2020 | |
| Gilead Sciences, INC. | $23.47 | 2021 | |
| Mirati Therapeutics, INC. | $23.40 | 2024 | Krazati |
| Adaptive Biotechnologies Corporation | $21.40 | 2023 | Clonoseq |
| Syndax Pharmaceuticals, INC. | $20.09 | 2025 | |
| Abbott Laboratories | $19.76 | 2023 | Jeti |
| Recor Medical INC | $19.56 | 2025 | Paradise Ultrasound Renal Denervation System |
| Legend Biotech USA INC. | $19.16 | 2025 | Carvykti |
| Apellis Pharmaceuticals, INC. | $18.93 | 2023 | Empaveli |
| Secura Bio, INC. | $17.82 | 2024 | Copiktra |
| Spectrum Pharmaceuticals INC. | $17.48 | 2023 | Rolvedon |
| Iovance Biotherapeutics, INC. | $15.39 | 2025 | Amtagvi |
| Stemline Therapeutics INC. | $14.82 | 2025 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $14.79 | 2021 | |
| Heron Therapeutics, INC. | $14.14 | 2021 | |
| Recordati_rare_diseases_inc. | $13.88 | 2025 | Enjaymo |
| Blueprint Medicines Corporation | $12.27 | 2021 | |
| Amag Pharmaceuticals, INC. | $11.86 | 2019 | |
| Myovant Sciences INC. | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavan Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.